The Alliance for Regenerative Medicine Announces Its Third Annual Regen Med Investor Day & Initial Slate of Presenting Companies
WASHINGTON, DC (PRWEB) February 03, 2015 -- The Alliance for Regenerative Medicine (ARM) today announced its annual Regen Med Investor Day will take place March 25, 2015 in New York City, co-hosted by top financial firm Piper Jaffray. Now in its third year, this one-day meeting remains the only investment event organized specifically to provide institutional, strategic and venture investors with unique insights into the financing hypothesis for advanced therapies-based treatments and technology.
The program will begin with Edward Lanphier, ARM chairman and president and CEO of Sangamo BioSciences, providing welcome remarks. Featured speaker, Olivier Danos, SVP, gene therapy of Biogen Idec, will then participate in a moderated fireside chat discussing the future outlook for advanced therapies and providing investors with an in-depth look at the role big pharma will play in the growth of the field.
“This sector’s focus on accelerating advances for patients with unmet medical needs is unparalleled,” said Edward Tenthoff, managing director and senior research analyst, Piper Jaffray. “Regenerative medicine and advanced therapies are where the next generation of medical innovation lies, providing ample investment opportunities to support this crucial area of therapeutic development.”
The program’s initial slate of presenting companies was selected on the basis of upcoming key milestones, innovative technologies and investor validation. Additional companies and speakers will be announced in the coming weeks.
2015 Presenting Companies:
AGTC, Argos Therapeutics, Audentes Therapeutics, Avalanche Biotechnologies, BrainStorm Cell Therapeutics, Capricor Therapeutics, Cardio3 BioSciences, Cellular Dynamics International, Histogenics, Juventas Therapeutics, MiMedx, NeoStem, Osiris Therapeutics, Pluristem Therapeutics, ReNeuron, Sangamo BioSciences, TiGenix, TxCell, ViaCyte, Voyager Therapeutics
In addition to presentations from leading international companies, the event will include three panels featuring research analysts covering the space, key clinical opinion leaders and top company CEOs. These discussions will explore themes specific to cell and gene therapy such as commercialization, market access and pricing for breakthrough technologies, gene therapy delivery and its continued evolution and upcoming milestones in the adoptive T-cell therapy space.
This event is held in partnership with Piper Jaffray and supporting bank Maxim Group. Additional sponsors include Lonza, NeoStem and Progenitor Cell Therapy (PCT). For more information, please visit the event’s website at http://www.arminvestorday.com. Credentialed investors, life science strategic partners and members of the media can indicate their interest in attending here.
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 200 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.
Michelle Linn, Linnden Communications, +1 (774) 696-3803, [email protected]
Share this article